Zimmer Biomet Holdings Stock News

The US knee implants market is expected to be highly consolidated owing to the growth in knee implant industry in the entire healthcare sector. Smith & Nephew, Johnson & Johnson, Stryker Corp., and Zimmer Biomet Holdings Inc. are the four

Equities research analysts expect Zimmer Biomet Holdings, Inc. (NYSE:ZBH) to announce $2.06 billion in sales for the current quarter, Zacks reports. Nine analysts have made estimates for Zimmer Biomets earnings, with estimates ranging from $2.04 billion to $2.08 billion. Zimmer Biomet reported sales of $2.09 billion during the same quarter last year, which would suggest []

Zimmer Biomet Holdings Inc (ZBH) shares closed today at 0.6% above its 52 week low of $124.83, giving the company a market cap of $26B. The stock is currently down 18.1% year-to-date, down 15.6% over the past 12 months, and up 27.6% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 34.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -456.2% The company's stock price performance over the past 12 months lags the peer average by -228.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 0.4% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Key Players covered in the Knee Replacement Market Research Report are Zimmer Biomet (Indiana, U.S.), Stryker (Michigan, U.S.), DePuySynthes Companies (Johnson & Johnson Services, Inc.) (Indiana, U.S.), Smith & Nephew (London, U.K.), Aesculap, Inc. a B. Braun company (Center Vally, USA), Medacta International (Castel San Pietro, Switzerland), MicroPort Scientific Corporation (Shanghai, China), Conformis (Massachusetts, U.S.), Other Prominent Players. Key Players covered in the Knee Replacement Market Research Report are Zimmer Biomet (Indiana, U.S.), Stryker (Michigan, U.S.), DePuySynthes Companies (Johnson & Johnson Services, Inc.) (Indiana, U.S.), Smith & Nephew (London, U.K.), Aesculap, Inc. a B. Braun company (Center Vally, USA), Medacta International (Castel San Pietro, Switzerland), MicroPort Scientific Corporation (Shanghai, China), Conformis (Massachusetts, U.S.), Other Prominent Players.

Gofen & Glossberg LLC IL trimmed its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.3% in the 3rd quarter, HoldingsChannel reports. The firm owned 5,209 shares of the medical equipment providers stock after selling 236 shares during the quarter. Gofen & Glossberg LLC ILs holdings in Zimmer Biomet were worth $762,000 at the end []

Overview: Surgical robots allow doctors to perform complex procedures with more precision, flexibility, and control than traditional techniques. Robotic technology is helpful because of the smaller incisions, which result in less postoperative pain, lower morbidity, and shorter hospital stays, which is

Stem cell concentration system further helps to obtain viability and proliferative potential of stem cell expected to gaining more traction and drive the stem cell concentration system market. The Global Stem Cell Concentration System Market Report provides planned insights into the

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reached a new 52-week low during trading on Tuesday . The company traded as low as $127.12 and last traded at $128.80, with a volume of 1584 shares traded. The stock had previously closed at $130.22. A number of equities research analysts recently commented on the company. Zacks Investment Research […]

Knee Cartilage Damage Repair Market research report is wide-ranging and object-oriented which is framed after the combination of an admirable industry experience, talent solutions, industry insight, and most modern tools and technology. A thorough analysis has been performed in this

Argus lowered shares of Zimmer Biomet (NYSE:ZBH) from a buy rating to a hold rating in a report published on Tuesday, Price Targets.com reports. A number of other equities analysts have also commented on ZBH. Canaccord Genuity reduced their target price on shares of Zimmer Biomet from $190.00 to $185.00 and set a buy rating []

IFP Advisors Inc grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 47.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,828 shares of the medical equipment providers stock after purchasing an additional 592 shares during the period. IFP Advisors []

Total Knee Arthroplasty Market has witnessed continuous growth in the past few years and is projected to grow even further during the forecast period (2021-2028). The research presents a complete assessment of the market and contains Future trend, Current Growth

The third quarter brings greater COVID-related pressure than expected for Zimmer Biomet (ZBH).

Marshall Wace LLP cut its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 70.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,669 shares of the medical equipment providers stock after selling 59,429 shares during the quarter. Marshall Wace LLPs holdings in []